Open AccessLipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function
Author(s) -
Cynthia Connolly,
Jessica Li,
Daniel Goldman,
Andrea Fava,
Laurence S. Magder,
Michelle Petri
Publication year - 2022
Publication title -
lupus
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.069
H-Index - 103
eISSN - 1477-0962
pISSN - 0961-2033
DOI - 10.1177/09612033221111958
Subject(s) - medicine , lupus nephritis , renal function , proteinuria , logistic regression , nephritis , population , lipoprotein(a) , systemic lupus erythematosus , kidney disease , rheumatology , gastroenterology , disease , immunology , lipoprotein , kidney , cholesterol , environmental health
Proteinuria is the clinical expression of lupus nephritis and despite recent advances in the therapeutic armamentarium for lupus nephritis, morbidity and mortality rates remain high. Therefore, the identification of factors that predict lupus nephritis is paramount in preventing damage accrual and disease progression. Lipoprotein (a) (Lp[a]) is a primarily genetically inherited plasma lipoprotein with pro-thrombotic and pro-atherosclerotic effects. Elevated Lp(a) has been observed at early stages of renal impairment in the general population and is associated with the development of chronic kidney disease. However, little is known about renal implications of Lp(a) in SLE. Thus, we evaluated Lp(a) and atherosclerotic events, thrombotic events, renal disease, and disease activity in patients with SLE.